Lymphoid populations and tumor disseminated cells in the bone marrow in early breast cancer

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. The study of lymphoid populations is a necessary step for understanding the interaction between the tumor and the immune system, as well as for a detailed analysis of the persistence of tumor cells in the bone marrow of patients with breast cancer. Lymphoid populations of the bone marrow can serve as a potential point of application for immunotherapy.

Aim. To study the composition of lymphoid populations and assess the relationship with disseminated tumor cells in the bone marrow of patients with operable breast cancer

Materials and methods. The study included 65 bone marrow samples obtained by sternal puncture in patients with breast cancer. Ductal adenocarcinoma stage T1 / T2, N0 status prevailed. Luminal A was detected in 51.3 %, luminal B 10.3 %, Erb-B2 overexpressing subtype was established in 15.4 % and triple-negative subtype in 6.4 %. T cells (CD3), B cells (CD19), NK cells (CD56+CD3– ), minor populations of TCRγδ and TCRαβ lymphocytes, CD4+CD25+ T cells, subpopulations of CD10+, CD38+, CD5+ B cells were studied. CD45+EpCAM+ cells among myelokaryocytes of a bone marrow sample were assessed. An immunological study of bone marrow using monoclonal antibodies (Becton Diskinson, USA) was performed on a FACS Canto II flow cytometer. The results were analyzed using the Kaluza Analysis v.2.1 program.

Results. A relationship was established between CD19+CD10+ cells and the morphological type of breast cancer: their increased content was noted in ductal adenocarcinoma (p ≤0.05). There was a relationship between lymphogenous metastasis and the level of CD5+CD38+ cells (p ≤0.05). In high-grade cancer, there was an increase in the proportion of CD4+CD25+ cells, estrogen-positive tumors were distinguished by the predominance of NK cells in the bone marrow (p ≤0.05). T-lymphoid populations are associated with the presence of disseminated tumor cells in the bone marrow. An increase in the proportion of CD4+CD25+ with a decrease in the number of CD3+HLA-DR+ and B-cells was noted (p = 0.03).

Conclusion. Lymphoid populations of the bone marrow are associated with the morphological characteristics of breast cancer. In metastatic bone marrow lesions, the proportion of T-cell lymphoid populations changes and the number of B-cells decreases.

About the authors

Svetlana V. Chulkova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University (Pirogov University), Ministry of Health of Russia

Author for correspondence.
Email: chulkova@mail.ru
ORCID iD: 0000-0003-4412-5019
Russian Federation, 24 Kashirskoe Shosse, Moscow 115522; Build. 6, 1 Ostrovityanova St., Moscow 117513

Elena N. Sholokhova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: chulkova@mail.ru
ORCID iD: 0000-0002-1456-1904
Russian Federation, 24 Kashirskoe Shosse, Moscow 115522

Olga P. Kolbatskaya

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: chulkova@mail.ru
ORCID iD: 0000-0001-8493-9012
Russian Federation, 24 Kashirskoe Shosse, Moscow 115522

Irina A. Gladilina

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University (Pirogov University), Ministry of Health of Russia

Email: chulkova@mail.ru
ORCID iD: 0000-0002-2481-0791
Russian Federation, 24 Kashirskoe Shosse, Moscow 115522; Build. 6, 1 Ostrovityanova St., Moscow 117513

Angelina V. Egorova

N.I. Pirogov Russian National Research Medical University (Pirogov University), Ministry of Health of Russia

Email: chulkova@mail.ru
ORCID iD: 0000-0003-3904-8530
Russian Federation, Build. 6, 1 Ostrovityanova St., Moscow 117513

Ivan S. Stilidi

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: chulkova@mail.ru
ORCID iD: 0000-0002-0493-1166
Russian Federation, 24 Kashirskoe Shosse, Moscow 115522

Tatiana N. Zabotina

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: chulkova@mail.ru
ORCID iD: 0000-0001-7631-5699
Russian Federation, 24 Kashirskoe Shosse, Moscow 115522

References

  1. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. doi: 10.3322/caac.21492
  2. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49. doi: 10.3322/caac.21660
  3. Esteva F.J., Hubbard-Lucey V.M., Tang J., Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol 2019;20(3):e175–86. doi: 10.1016/S1470-2045(19)30026-9
  4. Liu B., Fan Y., Song Z. et al. Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer. Int Immunopharmacol 2020;89(Pt B):107078. doi: 10.1016/j.intimp.2020.107078
  5. Ryabchikov D.A., Abdullaeva E.I., Dudina I.A. et al. The role of micro-RNA in carcinogenesis and prognosis of breast malignancies. Vestnik Rossiiskogo nauchnogo tsentra rentgenoradiologii = Bulletin of the Russian Scientific Center of X-ray Radiology 2018;18(2):1–20. (In Russ.).
  6. Sinn B.V., Weber K.E., Schmitt W.D. et al. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Res 2019;21(1):142. doi: 10.1186/s13058-019-1231-z
  7. Ryabchikov D.A., Beznos O.A., Dudina I.A. et al. Disseminated tumor cells in patients with luminal breast cancer. Rossijskij bioterapevticeskij zurnal = Russian Journal of Biotherapy 2018;17(1):53–7. (In Russ.). doi: 10.17650/1726-9784-2018-17-1-53-57
  8. Titov K.S., Kazakov A.M., Baryshnikova M.A. et al. Some molecular and immunological factors of prognosis of triple negative breast cancer. Onkoginekologiya = Oncogynecology 2019;32(4):26–34. (In Russ.). doi: 10.52313/22278710_2019_4_26
  9. Ryabchikov D.A., Vorotnikov I.K., Talipov O.A. et al. MicroRNAs and their role in the pathogenesis and diagnosis of breast cancer. Meditsinskiy alfavit = Medical Alphabet 2020;8:12–5. (In Russ.). doi: 10.33667/2078-5631-2020-8-12-15
  10. Capietto A.H., Faccio R. Immune regulation of bone metastasis. Bonekey Rep 2014;3(1):600. doi: 10.1038/bonekey.2014.95
  11. Tupitsyn N.N. Bone marrow of an oncology patient: tumor staging, hematopoiesis, immune system. Immunologiya gemopoeza = Immunology of hematopoiesis 2018;2(16):10–54. (In Russ.).
  12. Tupitsyn N.N., Dzhumanazarov T.M., Palladina A.D. et al. Immunological parameters of bone marrow in patients with non-small cell lung cancer. Rossijskij bioterapevticeskij zurnal = Russian Journal of Biotherapy 2020;19(2):47–54. (In Russ.). doi: 10.17650/1726-9784-2020-19-2-47-54
  13. Chulkova S.V., Sholokhova E.N., Poddubnaya I.V. et al. Relationship between lymphoid populations (infiltration) of the primary tumor and immune responses in the bone marrow of breast cancer patients. Rossijskij bioterapevticeskij zurnal = Russian Journal of Biotherapy 2023;22(1):49–61. (In Russ.). doi: 10.17650/1726-9784-2023-22-1-49-61
  14. Hartkopf A.D. et al. Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse. Ann Oncol 2015;26(6):1155–60. doi: 10.1093/annonc/mdv148
  15. Chulkova S.V., Tupitsyn N.N., Dzhumanazarov T.M. et al. Detection of disseminated tumor cells in the bone marrow of patients with non-small cell lung cancer. Rossijskij bioterapevticeskij zurnal = Russian Journal of Biotherapy 2020;19(3):29–37. (In Russ.). doi: 10.17650/1726-9784-2020-19-3-29-37
  16. Feuerer M., Rocha M., Bai L. et al. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int J Cancer 2001;92(1):96–105. PMID: 11279612
  17. Grigorieva T.A., Beznos O.A., Tupitsyn N.N. et al. Bone marrow lymphocyte subpopulations in patients with breast cancer. Tumors of the female reproductive system 2015;11(2):52–5. (In Russ.). doi: 10.17650/1994-4098-2015-11-2-52-55
  18. Lugovskaya S.A., Pochtar M.E. Morphology of bone marrow cells in norm and pathology, interpretation of myelograms. Moscow; Tver: Triada, 2018. 246 p. (In Russ.).
  19. Stankovic B., Bjоrhovde H.K., Skarshaug R. et al. Immune cell composition in human non-small cell lung cancer. Front Immunol 2019;9(А):3101. doi: 10.3389/fimmu.2018.03101
  20. Garaud S., Buisseret L., Solinas C. et al. Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight 2019;5(18):e129641. doi: 10.1172/jci.insight.129641
  21. Park H.B., Paik D.J., Jang E. et al. Acquisition of anergic and suppressive activities in transforming growth factor-beta-costimulated CD4+CD25– T cells. Int Immunol 2004;16(8):1203–13. doi: 10.1093/intimm/dxh123
  22. Whiteside T.L. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 2014;63(1):67–72. doi: 10.1007/s00262-013-1490-y
  23. Roychoudhuri R., Eil R.L., Restifo N.P. The interplay of effector and regulatory T cells in cancer. Curr Opin Immunol 2015;33:101–11. doi: 10.1016/j.coi.2015.02.003
  24. Buchan S.L., Rogel A., Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. 2018;131(1):39–48. doi: 10.1182/blood-2017-07-741025
  25. Starzer A.M., Berghoff A.S. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open 2020;4(Suppl. 3): e000629. doi: 10.1136/esmoopen-2019-000629

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 ABV-Press

License URL: https://bioterapevt.abvpress.ru/jour/about/editorialPolicies
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-53039 от  04.03.2013.